Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 plus Chemotherapy in Advanced Non-Squamous NSCLC with MPE
NCT06769295Phase 2Recruiting
- Sponsor
- Sichuan University
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), malignant pleural effusion (MPE), sponsored by Sichuan University. Started Feb 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT06769295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06769295.